Will SGK public coverage with Allianz Sigorta, Anadolu Sigorta, and Acibadem Sigorta employer plans cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Miplyffa is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by TITCK?

The TITCK named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; TITCK review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Turkish-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Turkish Medical Association (TTB) and the Ministry of Health licensing directorate verifies the active license; the TITCK application records both the prescribing physician and the dispensing facility.

Can I receive Miplyffa at home?

The dispensing facility must be Turkish-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 24,000 to 30,000 per month. Delivered quote within 24h.Get my quote

Miplyffa access in Turkey: the TITCK named-patient pathway

How patients in the Republic of Turkiye legally obtain Miplyffa (arimoclomol) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Turkey access Miplyffa (arimoclomol) for neurologic manifestations of Niemann-Pick disease type C in adult and pediatric patients 2 years of age and older, in combination with miglustat through the TITCK named-patient pathway, a the Turkish Medicines and Medical Devices Agency (Turkiye Ilac ve Tibbi Cihaz Kurumu)-administered mechanism that allows a Turkish-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in TRY.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Miplyffa reaches patients in Turkey

Miplyffa (arimoclomol, an oral heat-shock-protein co-inducer, FDA-approved September 2024 for neurologic manifestations of Niemann-Pick disease type C in adult and paediatric patients 2 years of age and older in combination with miglustat; marketed by Zevra Therapeutics) is not currently visible on the TITCK registered-product list at titck.gov.tr/dinamikmodul/43 as of 2026-05-31. Turkish patients access Miplyffa through the Yurt Dışından İlaç Temini named-patient programme under Additional Article 7 of Law No. 1262 and TITCK Kılavuzu Revision 14 at portal.aifd.org.tr TITCK Kılavuzu Rev. 14. The treating paediatric neurologist or adult neurologist files to the TITCK Commission for Evaluation of Medicines in Personal Treatment. The Miplyffa-specific clinical justification must document confirmed NPC diagnosis by NPC1 or NPC2 gene sequencing or by filipin staining of skin fibroblast cultures, age 2 years or older, the intended combination with miglustat (Zavesca, locally registered and SGK-formulary), baseline NPC Clinical Severity Score (NPCCSS) or the National Niemann-Pick Disease Foundation NPC severity scale, and the prescribing neurologist's tertiary-centre affiliation. Miglustat is the SGK-default and Miplyffa adds to rather than replaces it (per the FDA label combination requirement). TITCK clinical-approval turnaround for confirmed-NPC rare-disease cases is typically prioritised given the documented disease severity.

Where Miplyffa is dispensed in Turkey

Miplyffa is an oral chronic combination therapy administered in paediatric and adult neurology outpatient settings with neurological-symptom-progression surveillance using the NPCCSS or equivalent instruments. Turkish tertiary nodes for NPC and lysosomal storage disease include the Hacettepe University İhsan Doğramacı Children's Hospital Department of Paediatric Metabolic Disorders in Ankara at hastane.hacettepe.edu.tr, the country's longest-standing inherited-metabolic-disease reference centre with extensive NPC patient cohorts; Ege University Faculty of Medicine Department of Paediatrics Metabolic Diseases in Izmir; Istanbul University Çapa Faculty of Medicine Department of Paediatric Metabolic Diseases; Marmara University Pendik Training and Research Hospital Department of Paediatric Neurology in Istanbul; Behçet Uz Children's Hospital Department of Paediatric Neurology in Izmir; Dr. Sami Ulus Maternity and Children Training and Research Hospital Department of Paediatric Neurology in Ankara; Acıbadem Hospitals Paediatric Neurology Service (private tertiary); and Memorial Şişli Hospital Paediatric Neurology. Hacettepe is the country's NPC reference centre nationally and publishes faculty rosters; Hacettepe-led research on NPC clinical natural history in the Turkish cohort is well-documented. Adult NPC patients aging out of paediatric services transition to adult neurology at the affiliated university hospital adult neurology department.

What Miplyffa costs in Turkey

The US reference WAC for Miplyffa is approximately USD 30,000 to USD 35,000 per 30-day supply at maintenance dose per Zevra Therapeutics disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual US WAC at maintenance runs USD 360,000 to USD 420,000. The Miplyffa FDA label requires combination with miglustat (Zavesca, locally registered in Turkey and on the SGK formulary at a much lower TRY price); the combined regimen cost includes both. Under the SGK Yurt Dışından İlaç Temini reimbursement framework, named-patient reimbursement of Miplyffa is at the foreign-sourced price exempt from international reference pricing. No public TRY benchmark for Miplyffa is observed on TITCK or SGK pages as of 2026-05-31 because pricing is per-transaction. Do not estimate. Price snapshot: 2026-05-31. The TRY/USD spot rate from the Central Bank of Türkiye on the date of any quote should be footnoted. Cost layers for SGK-insured paediatric or adult NPC patients: drug cost mostly absorbed by SGK; co-payments and administrative fees; dispensing through TEB or USHAŞ; miglustat from SGK formulary at low TRY co-pay; and Reserve Meds concierge fee where US-sourced product or expedited timing is preferred.

Funding and access barriers for Miplyffa in Turkey

NPC is an ultra-rare lysosomal storage disease with estimated incidence approximately 1 in 100,000 live births. The Turkish NPC patient cohort, while small in absolute terms, is well-characterised at Hacettepe and other tertiary metabolic-disease centres given consanguinity rates supporting rare autosomal recessive disease prevalence. The historical pharmacological landscape has been limited to miglustat (Zavesca) for substrate-reduction therapy, supportive care, and (until withdrawal) intracerebroventricular hydroxypropyl-beta-cyclodextrin in selected centres. Miplyffa as the first FDA-approved disease-modifying therapy in combination with miglustat represents a meaningful clinical advance. Public funding: SGK reimbursement under Yurt Dışından İlaç Temini is the dominant funding pathway; SGK adjudication of confirmed-NPC paediatric and adult cases is generally favourable given the absence of locally-registered disease-modifying alternatives and the documented disease severity. For SGK-insured patients (the vast majority of Turkish residents), full reimbursement is generally available. Private health insurers (Acıbadem Sigorta, Anadolu Sigorta, AXA Sigorta, Allianz Sigorta, Mapfre Sigorta, Generali, Türk Nippon Sigorta) are supplementary. The İTS drug-tracking-system requirement adds a track-and-trace step. Zevra Therapeutics compassionate-access for confirmed-NPC patients operates case-by-case at early-launch stage in 2025-2026. The dispensing channel through TEB or USHAŞ is the mandatory route.

Recent regulatory and access news for Miplyffa

FDA approved Miplyffa on 20 September 2024 for neurologic manifestations of NPC in adult and paediatric patients 2 years and older in combination with miglustat, based on the CT-ORZY-NPC-002 trial; the first FDA-approved disease-modifying therapy for NPC. The FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. EMA review of arimoclomol is in progress; live status at ema.europa.eu/medicines. The International Niemann-Pick Disease Alliance has published patient and physician resources on Miplyffa initiation including dose titration protocols. TITCK published Revision 14 of the Yurt Dışından İlaç Temini ve Kullanımı Kılavuzu on 29 August 2024; the İTS regulation per Anadolu Ajansı applies to Miplyffa imports.

Where Reserve Meds fits in Miplyffa cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace TITCK, and we do not replace your dispensing pharmacy. For Miplyffa specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Turkey, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Miplyffa case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the TITCK application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Turkish specialty care concentrates at the Acibadem, American Hospital, and Memorial chains in Istanbul, with Hacettepe University Hospital in Ankara serving as the principal academic referral centre; the TITCK named-patient supply pathway is routed through the Turkish Pharmacists Association (TEB) foreign medicines channel.

Next step

If your Turkish physician has prescribed Miplyffa and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Miplyffa case Or message us on WhatsApp